Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

New research at the Kennedy Institute reveals potential of a novel class of drugs for the treatment of rheumatoid arthritis.

cIAP inhibitors restore a healthy balance between inflammatory and regulatory T lymphocytes to reduce inflammatory arthritis
Load More

Anti-TNF Drugs

Similar stories

NDORMS hosts international workshop to advance therapeutic discovery in chondrosarcoma

Researchers, clinicians, industry partners, bone cancer charities and patients recently gathered at St Catherine’s College, University of Oxford, for the inaugural ‘Oxford Workshop on Systems Biology and Therapeutic Approaches in Chondrosarcoma’. The event brought together expertise across research and clinical care with the long-term aim to improve outcomes for patients with chondrosarcoma.